A Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-Line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer

A Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-Line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer

Trial Category:
Lung
Phase
II
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Southeast Nebraska Cancer Center, Lincoln, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members